← boardnext 2026-07-30
TTRX
Tern Therapeutics, LLCdistress 2/10 · well-funded / low risk$9.62-5%today-5% from 52w high
Immunology / Inflammation 1
Lead: moderate-to-severe atopic dermatitis · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$11M
Runway
3.1 yrs
Shares 1y
+1%
Price & events
+103.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.5%
1D
+0.4%
1W
+66.7%
1M
+182.1%
3M
+103.4%
6M
—
1Y
—
2Y
—
5Y
+37.4%
All
Overview
- Market Cap
- $286.56M
- Enterprise Value
- $281.49M
- Volume
- 50.70K
- 52 Week Range
- $2.71 – $10.18
- Total Shares
- 29.79M
- Float Shares
- 10.83M
- % Held by Insiders
- 54.12%
- % Held by Institutions
- 2.51%
- RVOL
- 0.51x
Pipeline stages · 1 programs
TTX-381
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 14
- 2026readoutPhase 2GX-03 · topline results for GX-03 phase 2 trialSEC 8-K
- mid-2026readoutPhase 2GX-03 · Topline results from Phase 2 RCTSEC 8-K
- mid-2026readoutPhase 2GX-03 · Topline results from Phase 2 randomized controlled trialSEC 8-K
- mid-2026readoutPhase 2GX-03 · Topline data from Phase 2 adaptive trialSEC 8-K
- first half of 2026readoutPhase 2GX-03 · Phase 2 trial interim and topline data expectedSEC 8-K
- mid-2026readoutPhase 2GX-03 · Topline results from Phase 2 trial for moderate-to-severe atopic dermatitis.SEC 8-K
- mid-2026readoutPhase 2GX-03 · Topline results from Phase 2 trial expected in mid-2026SEC 8-K
- June 4, 2026conferencedata presentationsecondaryCEO Bradley Burnam to present at Jefferies Global Healthcare ConferenceSEC 8-K
- June 4, 2026conferencedata presentationsecondaryPhase 2GX-03 · Jefferies Global Healthcare conference presentationSEC 8-K
- 2026-06-03conferencedata presentationsecondaryInvestor presentation at Jefferies Global Healthcare ConferenceSEC 8-K
- early 2026readoutPhase 2GX-03 · Topline data from lead program in severe eczemaSEC 8-K
- Monday, March 2, 2026 1:10 p.m. – 1:40 p.m. Eastern Timeconferencedata presentationsecondaryTD Cowen Healthcare Conference in BostonSEC 8-K
- Wednesday, February 25, 2026 8:00 a.m. – 8:30 a.m. Eastern Timeconferencedata presentationsecondaryOppenheimer Healthcare Life Sciences Conference (virtual) presentationSEC 8-K
- 2025-10-30partnershipPermaFusion · Global supply, development, and license agreement with Medline to develop, manufacture, and commercialize products using PermaFusion delivery platform.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-24D. Boral CapitalBuy
- 2026-01-20D. Boral CapitalBuy
- 2025-12-29D. Boral CapitalBuy
Competitors — moderate-to-severe atopic dermatitis
Recent news
- 2026-07-22Enterprise value to revenue forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
- 2026-07-21Turn Therapeutics Inc. Common Stock (NASDAQ: TTRX) Stock Price, News & Analysis - Kalkine
- 2026-07-19Why is Turn Therapeutics stock trading higher today? - MSN
- 2026-07-19Why is Turn Therapeutics stock trading higher today? - MSN
- 2026-07-16Turn Therapeutics (TTRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-16Turn Therapeutics (TTRX) Q4 2025 earnings summary - Quartr
- 2026-07-16Turn Therapeutics (TTRX) Corporate presentation Summary - Quartr
- 2026-07-15Turn Therapeutics: Small Market Cap, Huge Potential (NASDAQ:TTRX) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.